{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:10:37Z","timestamp":1793895037044,"version":"4.8.0"},"reference-count":15,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Of the side effects of prostaglandin analogues (PGAs), uveitis and cystoid macular oedema (CME) have significant potential for vision loss based on postmarket reports. Caution has been advised due to concerns of macular oedema and uveitis. In this report, we researched and summarised the original data suggesting these effects and determined their incidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Preferred Reporting Items for Systematic review and Meta-Analyses guidelines were followed. Studies evaluating topical PGAs in patients with ocular hypertension or open angle glaucoma were included. MEDLINE, PubMed, EMBASE, CINAHL, Web of Science, Cochrane Library, LILACS and ClinicalTrials.gov were searched between 1946 and 2019. Experimental studies, animal studies and randomised studies with other intraocular pressure-lowering eye drops were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>214 studies (28\u2009232 patients) met the inclusion criteria. Using prospective data, the incidence of uveitis and CME among PGA users were 62\/28 232 (0.22%) and 25\/28 232 (0.09%), respectively. A higher frequency of both uveitis and CME were found among latanoprost users compared with bimatoprost. There were 21 case studies reporting CME including 48 eyes in 43 patients. 47 of 48 eyes (97.9%) had previous incisional ocular surgery. 8 eyes were re-challenged, of which 7 (87.5%) recurred. 7 case studies reported uveitis in 15 eyes of 10 patients. 7 of 15 eyes (46.7%) were either pseudophakic or aphakic. 6 eyes were re-challenged, and all 6 (100%) recurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Cases of uveitis or CME revealed a confounding effect of ocular surgery, aphakia or subluxed intraocular lens. PGAs may be used in non-surgical patients without concern of causing CME or uveitis. The incidences of PGA-associated CME and uveitis are rare with limited prospective studies on the cause-effect relationship.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2019-315280","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T21:22:21Z","timestamp":1591996941000},"page":"1040-1044","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma"],"prefix":"10.1136","volume":"104","author":[{"given":"Jason","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-6863","authenticated-orcid":false,"given":"James Thinh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"2020080315452618000_104.8.1040.1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0014-4835(77)80043-2","article-title":"Prostaglandin and non-prostaglandin mediated breeakdown of the blood-aqueous barrier","volume":"25(Suppl)","author":"Eakins","year":"1977","journal-title":"Exp Eye Res"},{"key":"2020080315452618000_104.8.1040.2","first-page":"1125","article-title":"Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits","volume":"16","author":"Camras","year":"1977","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020080315452618000_104.8.1040.3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"key":"2020080315452618000_104.8.1040.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.07.002"},{"key":"2020080315452618000_104.8.1040.5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/jop.2013.0179","article-title":"Effects of prostaglandin analogues on aqueous humor outflow pathways","volume":"30","author":"Winkler","year":"2014","journal-title":"J Ocul Pharmacol Ther"},{"key":"2020080315452618000_104.8.1040.6","unstructured":"Pifer . Xalatan . Woodstock, IL: Catalent pharma solutions, 2012."},{"key":"2020080315452618000_104.8.1040.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(98)92977-3"},{"key":"2020080315452618000_104.8.1040.8","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850299"},{"key":"2020080315452618000_104.8.1040.9","unstructured":"Higgins JP , Green S , eds. Cochrane handbook for systematic reviews of interventions . John Wiley & Sons, 2011."},{"key":"2020080315452618000_104.8.1040.10","doi-asserted-by":"crossref","unstructured":"Liberati A , Altman DG , Tetzlaff J , et al . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.doi:10.1371\/journal.pmed.1000100","DOI":"10.1371\/journal.pmed.1000100"},{"key":"2020080315452618000_104.8.1040.11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00417-009-1036-3","article-title":"Efficacy and safety of latanoprost in eyes with uveitic glaucoma","volume":"247","author":"Markomichelakis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020080315452618000_104.8.1040.12","unstructured":"American Academy of Ophthalmology Glaucoma Panel . Preferred practice pattern guidelines. primary open-angle glaucoma . San Francisco, CA: American Academy of Ophthalmology, 2010."},{"key":"2020080315452618000_104.8.1040.13","first-page":"S7","article-title":"Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye","volume":"44 Suppl 1","year":"2009","journal-title":"Can J Ophthalmol"},{"key":"2020080315452618000_104.8.1040.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.131037"},{"key":"2020080315452618000_104.8.1040.15","doi-asserted-by":"crossref","unstructured":"Moher D , Liberati A , Tetzlaff J , et al . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.doi:10.1371\/journal.pmed.1000097","DOI":"10.1371\/journal.pmed.1000097"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2019-315280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T09:02:07Z","timestamp":1601110927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2019-315280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,23]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bjophthalmol-2019-315280"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315280","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]}}}